Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

The effect of metformin on glucose metabolism was examined in eight obese (percent ideal body weight, 151 +/- 9%) and six lean (percent ideal body weight, 104 +/- 4%) noninsulin-dependent diabetic (NIDD) subjects before and after 3 months of metformin treatment (2.5 g/day). Fasting plasma glucose (11.5-8.8 mmol/L), hemoglobin-A1c (9.8-7.7%), oral glucose tolerance test response (20.0-17.0 mmol/L; peak glucose), total cholesterol (5.67-4.71 mmol/L), and triglycerides (2.77-1.52 mmol/L) uniformly decreased (P less than 0.05-0.001) after metformin treatment; fasting plasma lactate increased slightly from baseline (1.4 to 1.7 mmol/L; P = NS). Body weight decreased by 5 kg in obese NIDD subjects, but remained constant in lean NIDD. Basal hepatic glucose production declined in all diabetics from 83 to 61 mg/m2.min (P less than 0.01), and the decrease correlated (r = 0.80; P less than 0.01) closely with the fall in fasting glucose concentration. Fasting insulin (115 to 79 pmol/L) declined (P less than 0.05) after metformin. During a 6.9 mmol/L hyperglycemic clamp, glucose uptake increased in every NIDD subject (113 +/- 15 to 141 +/- 12 mg/m2.min; P less than 0.001) without a change in the plasma insulin response. During a euglycemic insulin clamp, total glucose uptake rose in obese NIDD subjects (121 +/- 10 to 146 +/- 9 mmol/m2.min; P less than 0.05), but decreased slightly in lean NIDD (121 +/- 10 to 146 +/- 0.5; P = NS). Hepatic glucose production was suppressed by more than 80-90% in all insulin clamp studies before and after metformin treatment. In conclusion, metformin lowers the fasting plasma glucose and insulin concentrations, improves oral glucose tolerance, and decreases plasma lipid levels independent of changes in body weight. The improvement in fasting glucose results from a reduction in basal hepatic glucose production. Metformin per se does not enhance tissue sensitivity to insulin in NIDD subjects. The improvement in glucose metabolism under hyperglycemic, but not euglycemic, conditions suggests that metformin augments glucose-mediated glucose uptake. Metformin has no stimulatory effect on insulin secretion.

[1]  P. J. Randle,et al.  Immunoassay of insulin with insulin antibody preciptate. , 1963, Lancet.

[2]  G. Reaven,et al.  Effect of Chlorpropamide on Serum Glucose and Immunoreactive Insulin Concentrations in Patients with Maturity-onset Diabetes Mellitus , 1967, Diabetes.

[3]  A. Czyżyk,et al.  Effect of Biguanides on Intestinal Absorption of Glucose , 1968, Diabetes.

[4]  H. Lardy,et al.  Mode of action of hypoglycemic agents. V. Studies with phenethylbiguanide in isolated perfused rat liver. , 1973, The Journal of biological chemistry.

[5]  J. Karam,et al.  Antidiabetic drugs after the University Group Diabetes Program (UGDP). , 1975, Annual review of pharmacology.

[6]  G. Searle,et al.  Lactic Acidosis Associated with Phenformin Therapy: Evidence that Inhibited Lactate Oxidation is the Causative Factor , 1975, Diabetes.

[7]  S. Shalet,et al.  A comparison of phenformin and metformin in the treatment of maturity onset diabetes. , 1977, Diabete & metabolisme.

[8]  B. Clarke,et al.  Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. , 1977, British medical journal.

[9]  W. Tamborlane,et al.  RESTORATION OF NORMAL LIPID AND AMINOACID METABOLISM IN DIABETIC PATIENTS TREATED WITH A PORTABLE INSULIN-INFUSION PUMP , 1979, The Lancet.

[10]  P. Ravenscroft,et al.  Rapid liquid-chromatographic determination of metformin in plasma and urine. , 1981, Clinical chemistry.

[11]  R. DeFronzo,et al.  The Effect of Insulin on the Disposal of Intravenous Glucose: Results from Indirect Calorimetry and Hepatic and Femoral Venous Catheterization , 1981, Diabetes.

[12]  Lucis Oj.  The status of metformin in Canada , 1983 .

[13]  R. Prager,et al.  Insulin Receptor Binding to Monocytes, Insulin Secretion, and Glucose Tolerance Following Metformin Treatment: Results of a Double-Blind Cross-Over Study in Type II Diabetics , 1983, Diabetes.

[14]  R. Vigneri,et al.  Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients. , 1983, The Journal of clinical endocrinology and metabolism.

[15]  R. DeFronzo,et al.  Mechanism of Improvement in Glucose Metabolism After Chronic Glyburide Therapy , 1984, Diabetes.

[16]  B V Howard,et al.  Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. , 1984, The Journal of clinical investigation.

[17]  J. A. Scarlett,et al.  The Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic Subjects , 1984, Diabetes.

[18]  H. Gin,et al.  Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. , 1985, Metabolism: clinical and experimental.

[19]  R. DeFronzo,et al.  Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. , 1985, The Journal of clinical investigation.

[20]  J. Lord,et al.  Postreceptor effect of metformin on insulin action in mice , 1985, The Journal of pharmacy and pharmacology.

[21]  H. Graf,et al.  Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. , 1986, Diabete & metabolisme.

[22]  I. G. Fantus,et al.  Mechanism of action of metformin: insulin receptor and postreceptor effects in vitro and in vivo. , 1986, The Journal of clinical endocrinology and metabolism.

[23]  Bailey Cj,et al.  Effect of metformin on glucose metabolism in mouse soleus muscle. , 1986 .

[24]  J. Olefsky,et al.  Effects of Weight Loss on Mechanisms of Hyperglycemia in Obese Non-Insulin-Dependent Diabetes Mellitus , 1986, Diabetes.

[25]  J. Jaspan,et al.  Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes , 1987, Diabetes.

[26]  R. Vigneri,et al.  Direct effects of biguanides on glucose utilization in vitro. , 1987, Metabolism: clinical and experimental.

[27]  A. Avogaro,et al.  Effect of Metformin on Insulin-Stimulated Glucose Turnover and Insulin Binding to Receptors in Type II Diabetes , 1987, Diabetes Care.

[28]  R. DeFronzo,et al.  Role of Lipid Oxidation in Pathogenesis of Insulin Resistance of Obesity and Type II Diabetes , 1987, Diabetes.

[29]  R. Vigneri,et al.  Role of metformin in treatment of diabetes mellitus , 1987, Diabetes Care.

[30]  I. Campbell,et al.  Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes. , 1988, Journal of clinical pathology.

[31]  N. Wollen,et al.  Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. , 1988, Biochemical pharmacology.

[32]  C. J. Bailey,et al.  Metformin Revisited: Its Actions and Indications for Use , 1988, Diabetic medicine : a journal of the British Diabetic Association.

[33]  R. DeFronzo,et al.  Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. , 1989, Metabolism: clinical and experimental.

[34]  R G Shulman,et al.  Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. , 1990, The New England journal of medicine.

[35]  R. DeFronzo,et al.  Indirect calorimetry: methodological and interpretative problems. , 1990, The American journal of physiology.

[36]  G. Reaven,et al.  Effect of Metformin on Carbohydrate and Lipoprotein Metabolism in NIDDM Patients , 1990, Diabetes Care.